（编辑 袁冠琳） 证券日报网讯 迈克生物11月14日在互动平台回答投资者提问时表示，公司始终专注于体外诊断产品的 研发、生产、销售和相关服务，历经三十年发展，公司已具备研发制造体外诊断设备、试剂、校准品和 质控品的系统化专业能力，已完成从生物原材料、医学实验室产品到专业化服务的全产业链发展的布 局，正步入以自动化、智能化产品构建智慧化实验室的发展阶段。公司人工智能应用集中于体外诊断领 域，在AI辅助检测、图像识别等领域已取得一定成果；将人工智能、大数据模型应用于尿液、血球、 病理等项目上；公司的智慧化实验室解决方案通过实现从样本采集、传输、处理到检测结果的全流程智 能化管理。公司也在探索将人工智能的技术应用于更广泛的医疗领域。 ...

每经AI快讯，有投资者在投资者互动平台提问：公司是否有并购重组计划？ 迈克生物（300463.SZ）11月14日在投资者互动平台表示，公司目前暂无并购重组计划。 （文章来源：每日经济新闻） ...

每经AI快讯，有投资者在投资者互动平台提问：公司后续如何改善业绩？ （文章来源：每日经济新闻） 迈克生物（300463.SZ）11月13日在投资者互动平台表示，尽管面临市场内卷和前期投入带来的压力， 业绩有所承压，但我们认为推广"智慧化实验室"是必要的市场策略，有助于公司穿越行业周期并把握结 构性机会。目前，已有9家医院实际运行智慧化实验室系统，12家正在实施过程中，另有多家处于前期 方案设计阶段，详细情况请关注公司定期报告。 ...

证券代码：300463 证券简称：迈克生物 公告编号：2025-103 迈克生物股份有限公司 关于担保进展的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 一、担保情况概述 （一）成都欧润康生物科技有限公司 1、被担保人名称：成都欧润康生物科技有限公司 2、成立日期：2017年12月19日 迈克生物股份有限公司（以下简称"迈克生物"或"公司"）于2025年9月29日召开的第 六届董事会第六次会议、第六届监事会第六次会议，于2025年10月15日召开的2025年第三次临 时股东大会，审议通过了《关于为公司经销商向银行申请授信额度提供担保的议案》，同意在 风险可控的前提下，为符合条件的经销商向指定的银行申请授信额度不超过35,000万元人民币 提供连带责任保证担保，担保有效期自股东大会审议通过后一年有效。该额度在担保有效期内 可以滚动使用，为防控风险，公司对外提供担保时会同步要求被担保经销商向公司提供一定形 式的反担保。上述额度不等于公司实际担保金额，实际担保额度和期限以公司指定的银行、经 销商正式签署的相关协议为准。具体内容详见公司于2025年9月30日在巨 ...

Group 1 - Semiconductor Manufacturing International Corporation (SMIC) plans to acquire 47% equity in SMIC North, with due diligence and evaluation processes still ongoing [1][2] - Zhuhai Gree Supply Chain intends to convert a debt of 200 million yuan into equity to increase capital for Shenzhen Haoneng Technology, changing its status from a wholly-owned subsidiary to a controlling subsidiary [3] - China Huadian Corporation is set to invest 12.043 billion yuan in a combined heat and power generation project integrated with renewable energy in Heilongjiang [4] Group 2 - Yong'an Pharmaceutical announces that some directors and senior management plan to reduce their holdings by up to 0.0799% of the total shares [5] - Lihua Co. reports a 11.44% year-on-year increase in chicken sales revenue for October, totaling 1.461 billion yuan [6] - Degu Technology intends to terminate the acquisition of 100% equity in Haowei Technology due to difficulties in meeting the demands of all parties involved [7] Group 3 - Guocheng Mining plans to pay 3.168 billion yuan in cash to acquire 60% equity in Guocheng Industrial [8] - Yingtang Intelligent Control intends to acquire 100% equity in Guanglong Integration and 80% equity in Aojian Microelectronics, with stock resuming trading on November 10 [9] - Shanshan Holdings announces that its actual controller and major shareholder have divorced, resulting in a change in control [10] Group 4 - Nutaige plans to invest 100 million yuan to establish a wholly-owned subsidiary focused on robotics and related components [11] - Chengxing Co. reports that its Jiangyin factory is currently under temporary shutdown for rectification due to a raw material leak [12] - Xindong Holdings announces that its shareholder Hainan Zhuhua plans to reduce its stake by up to 3% [13] Group 5 - Yonghui Supermarket's vice president has completed a share reduction of 0.0012% [14] - Xi'an Tourism plans to issue A-shares to raise no more than 300 million yuan for working capital and bank loan repayment [15] - Xiaogoods City has successfully acquired land use rights for a commercial site in Yiwu for 3.223 billion yuan [16][17] Group 6 - Tongda Chuangzhi announces a cash dividend of 6 yuan per 10 shares for the 2025 interim period [18] - Shen Nan Electric A received a government subsidy of 8.0518 million yuan, accounting for 36.75% of its last fiscal year's net profit [19] - Founder Technology's subsidiary plans to invest 1.364 billion yuan in an AI expansion project in Chongqing [20] Group 7 - Hezhong China reports significant stock trading fluctuations, indicating a "hot potato" effect [21] - Hengrui Medicine's subsidiary has received approval for clinical trials of SHR-4610 injection for late-stage solid tumors [22] - Sihua Holdings announces the termination of a restructuring investment agreement and continues to seek potential investors [23] Group 8 - Yingwei Technology's subsidiary has won a 27.78% share of a project from China Mobile [24] - Dabeinong reports a 45.20% year-on-year increase in pig sales for October, totaling 5.79 billion yuan [25] - Meihua Biotech's major shareholder has been sentenced for market manipulation, but it does not affect the company's operations [26] Group 9 - Zhongyi Da plans to terminate the issuance of A-shares to specific investors [27] - Zhongji Oil and Gas has received a notice of investigation from the China Securities Regulatory Commission regarding trading violations [28] - China International Trade Corporation announces the resignation of its chairman due to work reasons [29] Group 10 - GAC Group reports a decline in October vehicle sales by 8.10% [30] - Dameng Data has invested 100 million yuan to establish an investment fund focused on the database industry [31] - Zhengbang Technology reports a 78.08% year-on-year increase in pig sales revenue for the first ten months [32] Group 11 - Shanghai Xiba has announced that its directors are under investigation for suspected short-term trading [33] - Changgao Electric New has won a bid for a project from the State Grid worth 246 million yuan [34] - Jianghuai Automobile reports a 5.49% increase in October sales [35] Group 12 - Xintian Green Energy reports a 20.97% year-on-year decrease in power generation for October [36] - Luokang Pharmaceutical's products have been selected in the national centralized procurement [37] - Zhongyuan Home intends to invest 16 million USD in a self-built production base in Vietnam [38] Group 13 - Changcheng Technology has terminated plans for a control change and will resume trading on November 10 [39] - Poly Development reports a significant decrease in signed sales area and amount for October [40] - Wanhua Chemical's MDI phase II facility will undergo maintenance starting November 15 [41]

Group 1 - Fangzheng Technology's subsidiary plans to invest 1.364 billion yuan in an AI expansion project in Chongqing to quickly increase production capacity [1] - The current production capacity at the Chongqing base cannot meet customer order demands, necessitating this investment [1] - The expansion aims to strategically optimize product structure and enhance the company's ability to meet the needs of high-end clients in AI, cloud computing, and big data sectors [1] Group 2 - Huadian Technology signed a contract worth approximately 3.415 billion yuan for a 1 million kW offshore wind power project, which constitutes about 45.29% of the company's latest audited revenue [2] - This contract is expected to have a positive impact on the company's operating performance [2] Group 3 - ST Huayun applied to revoke other risk warnings after receiving a penalty notice from the China Securities Regulatory Commission for false reporting from 2018 to 2022 [3] - The company has completed a review and found no conditions warranting the risk warning, thus meeting the criteria for revocation [3] Group 4 - Meihua Biological's controlling shareholder was sentenced to three years in prison (suspended for five years) for manipulating the securities market, but this matter does not affect the company's operations [4] - The company confirmed that its production and business activities remain normal despite the legal issues surrounding the shareholder [4] Group 5 - Shanghai Xiba's board members are under investigation for suspected short-term trading, but this investigation is personal and will not significantly impact the company's daily operations [5] Group 6 - Changcheng Technology terminated plans for a change in control due to a lack of consensus on key matters, and its stock will resume trading on November 10, 2025 [6] Group 7 - Hefei China reported a 23.91% year-on-year decline in consolidated revenue for the period from January to October 2025, totaling 587 million yuan [8] Group 8 - Various companies are involved in significant project wins and collaborations, including Rayco Defense acquiring minority stakes in a subsidiary and several companies winning contracts for large-scale projects [13]

Core Points - The company, Maike Bio, announced that it has received a medical device registration certificate from the National Medical Products Administration for its product, the Chlamydia pneumoniae IgG antibody test kit (direct chemiluminescence method) [1] Group 1 - The product is classified as an in vitro diagnostic reagent [1] - The announcement was made on the evening of November 7 [1]

Group 1 - Company plans to raise no more than 3.6 billion yuan through a private placement to fund seven projects, including a 500,000 kW green power project in Inner Mongolia [1] - Company has received acceptance for a clinical trial application for its self-developed drug for metastatic pancreatic ductal adenocarcinoma [1] - Company intends to establish a joint venture to implement a high-quality gallium arsenide chip construction project with a total investment of 272 million yuan [2] Group 2 - Company reported a revenue of 142 million yuan from pig sales in October, with a total sales volume of 162,800 pigs [3] - Company signed an annual procurement contract to supply 870,000 tons of electrolyte products from 2026 to 2028 [5] - Company plans to reduce its shareholding by up to 3% through various trading methods [7] Group 3 - Company intends to purchase 100 hydrogen fuel cell vehicles for a total price of 78.32 million yuan [9] - Company plans to acquire a 51% stake in a semiconductor equipment company for 510 million yuan [10] - Company has regained eligibility to participate in military procurement activities after being removed from the banned list [12] Group 4 - Company plans to establish a joint venture with state-owned funds for rural development with a total registered capital of 2.87 billion yuan [14] - Company reported a revenue of 1.918 billion yuan from pig sales in October, with a significant year-on-year increase [16][17] - Company plans to distribute a cash dividend of 0.01 yuan per share, totaling 7.9801 million yuan [18] Group 5 - Company has submitted an application for H-share listing on the Hong Kong Stock Exchange [19] - Company received approval for its convertible bond issuance application [20] - Company plans to establish a wholly-owned subsidiary with an investment of 70 million yuan focused on innovative medical research [22] Group 6 - Company reported a 33.87% year-on-year increase in sales volume for October [26] - Company has received a product designation from a leading new energy vehicle brand, with an expected total revenue of approximately 470 million yuan [28] - Company has initiated a key Phase III clinical trial for an innovative eye drop treatment for moderate to severe dry eye syndrome [30] Group 7 - Company reported a total automobile sales volume of 170,700 units in October, a year-on-year decrease of 8.1% [30] - Company plans to invest 16 million USD in establishing a production base in Vietnam [33] - Company has received a warning letter from the regulatory authority due to a breach of commitment by its controlling shareholder [52]

IGG(00799.HK)11月7日耗资49.2万港元回购13万股 迈克生物(300463.SZ)：肺炎衣原体IgG抗体检测试剂 盒取得产品注册证书 格隆汇11月7日丨IGG(00799.HK)发布公告，2025年11月7日耗资49.2万港元回购13万股，回购价格每股 3.77-3.8港元。 相关事件 ...

Core Viewpoint - The company, Mike Bio (300463.SZ), has received a medical device registration certificate from the National Medical Products Administration for its pneumonia chlamydia IgG antibody test kit, which is intended for auxiliary diagnosis of pneumonia chlamydia infection [1] Group 1 - The new product is compatible with the company's fully automated chemiluminescence immunoassay analyzers, including the i6000, i3000, i1000, and i800 series [1] - The company has accumulated a total of 140 registered reagent products under the direct chemiluminescence platform to date [1] - The registration of the new product enriches the company's product portfolio, enhancing its overall market competitiveness and positively impacting market expansion and future operations [1]